|
|
Research Focus
In addition to formulary and post-approval research conducted by Eisai Inc., the company also draws on Eisai Co., Ltd.'s global research and development capabilities - including basic and clinical research. Approximately 13 percent of Eisai's worldwide revenue is spent on research and development, with emphasis in the following therapeutic areas:
NeurologyA number of neurological illnesses call for effective new treatments, and the health care industry anticipates a high level of medical need and potential growth in the field of neurology. Eisai Co., Ltd.'s Tsukuba Research Laboratories in Japan has taken the lead in developing new drugs in this field, working closely with Eisai London Research Laboratories to maximize mutual strengths and build a research and development structure that will identify potential candidates to treat or cure certain neurological disorders. In addition, there are clinical programs at Eisai Medical Research Inc. in the United States for additional indications for Aricept® (donepezil hydrochloride tablets).
Gastrointestinal DisordersGastrointestinal disorders is another major therapeutic area of focus. In 2002, the U.S. Food and Drug Administration (FDA) approved Eisai's New Drug Application for the use of Aciphex® (rabeprazole sodium), in combination with appropriate antibiotics, for the eradication of H. pylori infection. H. pylori is a type of bacteria that researchers believe is responsible for the majority of peptic ulcers.
CancerEisai's cancer research is primarily conducted at the Oncology New Drug Development Research Laboratory of the Tsukuba Research Laboratories in Japan and the Eisai Research Institute in Andover, Massachusetts. Eisai Research Institute's strength is in the discovery and identification of molecules and naturally occurring biologically active compounds that have the potential to treat and prevent diseases. Researchers are making progress on substances with various mechanisms of action, including agents that inhibit cell division and blood vessel formation. Currently, Eisai is researching three promising drugs - a G1 cell cycle arresting agent in Phase II, a new tubulin antagonist in Phase I and a new angiogenesis inhibitor in Phase I.
Acute CareResearchers are investigating possible treatments for sepsis, a potentially fatal condition for which there are few effective treatments. One such drug, discovered by Eisai Research Institute in Andover, Massachusetts, is currently in Phase II clinical trials.
 Printer Friendly Version
|
|
